• Home
  • Shop
  • About
  • FAQ
  • Contact
  • Compare Peptides
  • Wholesale
  • PT-141 (Bremelanotide) – Research Compound Profile

    PT-141 (Bremelanotide) – Research Compound Profile

    Category: Hormonal Research | Molecular Type: Synthetic Cyclic Heptapeptide | Research Status: Not FDA-approved as supplied — research use only

    This page compiles published research data for qualified researchers. PT-141 (Bremelanotide) is sold exclusively as a research compound and is not approved for general human use outside its specific FDA-approved indication (Vyleesi®).

    Purchase for Research →

    Molecular Overview

    PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is an analog of α-melanocyte-stimulating hormone (α-MSH) and was originally identified as an active metabolite of Melanotan II through a carboxylation reaction [1][2]. Bremelanotide is classified as a non-selective melanocortin receptor (MCR) agonist with binding activity at MC1R, MC3R, MC4R, and MC5R subtypes [4][5].

    Several structural features matter for analytical characterization. The N-terminus is acetylated and the C-terminus is a free acid. The ring is closed by a lactam bridge between the aspartate side-chain carboxyl and the lysine side-chain amine, constraining the backbone so that the His-D-Phe-Arg-Trp pharmacophore — the conserved melanocortin message sequence — is presented in a receptor-competent orientation. Two non-proteinogenic substitutions distinguish it from native α-MSH: norleucine in place of methionine, removing an oxidation-prone thioether, and a D-phenylalanine at the position corresponding to Phe7, which stabilises the active conformation and blocks the principal chymotrypsin-like cleavage site. Together with cyclisation, these account for its markedly greater proteolytic stability relative to the linear parent hormone.

    In June 2019, the FDA approved bremelanotide under the trade name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it only the second pharmacotherapy approved for this indication [3]. The approval was based on two pivotal phase 3 RECONNECT randomized controlled trials enrolling 1,247 premenopausal women [3]. Outside of its approved indication, bremelanotide remains an investigational compound studied across several research domains including melanocortin neurobiology, sexual behavior pharmacology, and metabolic signaling.

    Mechanism of Action

    Unlike PDE5 inhibitors (e.g., sildenafil, tadalafil) that act peripherally on vascular smooth muscle, bremelanotide operates centrally through the melanocortin system — a neuroendocrine signaling network involved in appetite, reward, energy homeostasis, and sexual behavior [4][5]. The effects on sexual behaviour reported in the published literature are attributed primarily to MC4R activation in the central nervous system [4][5][10].

    The melanocortin receptors are class A G protein-coupled receptors signalling predominantly through Gαs, raising intracellular cyclic AMP and activating protein kinase A. Their tissue distribution explains the subtype-selectivity problem in this class: MC1R sits principally on melanocytes, MC3R and MC4R in the central nervous system, MC5R in exocrine tissue. Because bremelanotide is non-selective across MC1R, MC3R, MC4R, and MC5R, its observed profile reflects the sum of central and peripheral receptor engagement rather than a single pathway [4][5].

    When bremelanotide binds to MC4R on presynaptic neurons in the hypothalamus and limbic system, it triggers the release of dopamine into key reward and arousal circuits — specifically the nucleus accumbens, the medial preoptic area (mPOA), the ventral tegmental area, and the medial and basolateral amygdala [4][5]. These regions collectively govern the motivational, appetitive, and consummatory phases of sexual behavior. In preclinical models, MC4R agonism selectively facilitated solicitation behaviors in estrogen-primed female rats, demonstrating that the mechanism specifically amplifies sexual motivation rather than inducing non-specific arousal [17]. Functional MRI work in women with HSDD reported that bremelanotide significantly modulated brain activation patterns in response to sexual cues relative to placebo [11].

    In male models, bremelanotide’s erectogenic effect operates through a different downstream pathway: central MC4R activation ultimately stimulates nitric oxide (NO) release in the corpus cavernosum, producing vasodilation [1][2]. This distinguishes it mechanistically from PDE5 inhibitors, which prevent NO degradation rather than promoting its synthesis.

    Pharmacokinetics

    Published pharmacokinetic data report that bremelanotide has near-complete parenteral bioavailability, reaches peak plasma concentration in approximately 1 hour, and has a terminal half-life of approximately 2.7 hours (range 1.9–4.0 hours) [10][11]. It is 21% protein-bound, cleared by multiple hydrolysis reactions rather than by cytochrome P450 metabolism, and eliminated predominantly by the renal route with a smaller faecal contribution [10]. The short half-life means exposure is transient, so effects observed in acute paradigms cannot be extrapolated to sustained receptor occupancy. Peripheral MC1R engagement accounts for the melanogenesis and modest haemodynamic effects reported in the literature [4][16].

    Published Research Parameters

    The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

    Study / YearModelDurationKey ObservationReference
    Molinoff et al., 2003Preclinical (multiple models)VariedCharacterized bremelanotide as a melanocortin agonist with erectogenic and pro-sexual properties in preclinical models[1]
    Pfaus et al., 2004Ovariectomized female rats (estrogen-primed)AcuteSelective facilitation of sexual solicitation behavior via MC4R; no effect on non-sexual locomotor activity[17]
    Pfaus et al., 2007Preclinical rodent modelsVariedReviewed CNS effects on female sexual function; dopaminergic signaling in limbic circuits identified as primary mechanism[2]
    Clayton et al., 2016Premenopausal women with HSDD (Phase 2b, n=327)12 weeksExposure-finding study; one exposure group was carried forward into phase 3 (NCT01382719)[7]
    Kingsberg et al., 2019Premenopausal women with HSDD (Phase 3, RECONNECT, n=1,247)24 weeksStatistically significant improvements in FSFI-Desire domain and reductions in FSDS-DAO distress scores vs. placebo[3]
    Long-term Extension, 2019Premenopausal women with HSDD (Open-label extension)52 weeksEndpoint differences observed in the pivotal trials were sustained, with no new safety signal identified over the extension period[9]
    Ambulatory BP Study, 2017Human subjects (RCT, double-blind)Acute monitoringSmall, transient placebo-adjusted increases in systolic and diastolic blood pressure that resolved within the monitoring window[15]
    Obesity Trials, 2022Obese women (Phase 1, two RCTs)VariedInvestigated effects on body weight; nausea was exposure-limiting in the higher exposure groups[8]
    Ethanol Co-administration, 2017Healthy subjects (Phase 1, RCT)AcuteNo clinically significant pharmacokinetic interaction between bremelanotide and ethanol observed[18]

    Stability & Storage Characteristics

    Published stability data for bremelanotide report the following characteristics:

    • Lyophilized form: Stable for 24+ months when stored at −20 °C (−4 °F) in a dry, dark, desiccated environment [12]. The lyophilized cake is sensitive to moisture uptake; allowing vials to equilibrate to ambient temperature before opening reduces condensation exposure.
    • Ambient temperature tolerance: Brief exposure below 25 °C (77 °F) for up to 72 hours has been documented for transport conditions, though extended ambient storage is not recommended [12].
    • Light sensitivity: The compound should be protected from direct light during storage, consistent with general peptide handling literature [12]. The tryptophan residue in the message sequence is the most photolabile element of the molecule and the likeliest site of light-driven oxidative modification.
    • Adsorptive loss: In dilute working solutions, small cyclic peptides adsorb measurably to glass and untreated polypropylene surfaces, which biases quantitation; low-binding labware is a common control for this effect.

    Analytical Characterization

    Research-grade bremelanotide is characterized with an orthogonal analytical panel. Reverse-phase HPLC provides the primary purity measure and, for a cyclic peptide, resolves the ring-opened hydrolysis product — the most informative single degradation marker for this molecule. Electrospray mass spectrometry confirms the intact mass; because cyclisation removes one water molecule relative to the linear sequence, ring-closed and ring-opened species differ by 18 daltons. A peptide-content assay separates net peptide from residual counter-ion, water, and salt, since gravimetric vial mass overstates the peptide present. Researchers should retain the available lot documentation for each lot.

    Key Published Research Findings

    • Primary endpoint (Phase 3): In two phase 3 RECONNECT randomized controlled trials (n=1,247 premenopausal women with HSDD), Kingsberg et al. (2019) reported statistically significant differences from placebo in the co-primary FSFI-Desire domain endpoint in both studies [3].

    • Co-primary distress endpoint: In the same RECONNECT trials, the FSDS-DAO item 13 score also differed significantly from placebo in both studies [3].

    • Responder analyses: Kingsberg et al. (2019) reported that the proportion of participants meeting the General Assessment Questionnaire responder definition was significantly greater in the bremelanotide arm than in placebo, and a post hoc analysis of a secondary event-based measure was directionally consistent [3].

    • Integrated analysis: Kingsberg et al. reported an integrated effect size across the two pivotal studies that the authors characterised as small but statistically robust, and consistent in direction between the two trials [3].

    • Long-term extension: In a 52-week open-label extension study, the endpoint differences observed in the pivotal trials were sustained and no new safety signal was identified [9]. Separation from placebo in the phase 3 trials was present at the earliest evaluated time point (week 4) and persisted across the full 24-week observation period [3].

    • Central dopaminergic mechanism (Preclinical): In a 2004 study published in PNAS, Pfaus et al. demonstrated that a melanocortin receptor agonist selectively facilitated sexual solicitation behaviors in ovariectomized, estrogen-primed female rats without affecting non-sexual locomotor activity, supporting a specific motivational mechanism rather than non-specific arousal [17].

    • Functional neuroimaging evidence: A published fMRI study reported by Palatin Technologies found that bremelanotide significantly modulated brain activation patterns in response to sexual cues in women with HSDD relative to placebo, providing central-mechanism evidence consistent with the preclinical MC4R data [11].

    • Exposure-response characterization (Phase 2b): In a phase 2b exposure-finding trial (NCT01382719), Clayton et al. (2016) evaluated several exposure groups in 327 premenopausal women with HSDD; one group was carried forward into phase 3 on the basis of the observed balance between endpoint separation and tolerability [7].

    • Preclinical erectogenic mechanism: Molinoff et al. (2003) and Pfaus et al. (2007) described bremelanotide’s erectogenic properties in male preclinical models via central MC4R activation leading to nitric oxide release in the corpus cavernosum, distinguishing its mechanism from peripheral-acting PDE5 inhibitors [1][2].

    Regulatory Status

    • FDA Approval: Bremelanotide was approved by the FDA in June 2019 under the trade name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. It is available by prescription for that specific indication.
    • Prescribing Limitations: The Vyleesi® label specifies a maximum frequency of administration and identifies contraindications including uncontrolled hypertension and cardiovascular disease [6].
    • Research Use: When sold separately as a research peptide (outside the Vyleesi® branded product), PT-141 is intended for laboratory research purposes only and is not intended for human consumption.

    References

    1. Ann N Y Acad Sci (2003) — Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. View Source

    2. J Sex Med (2007) — Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. View Source

    3. Obstet Gynecol (2019) — Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). View Source

    4. Neurol Int (2022) — Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for treatment of female hypoactive sexual desire. View Source

    5. CNS Spectrums (2021) — The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. View Source

    6. ResearchGate (2022) — Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials. View Source

    7. Obstet Gynecol (2019) — Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder (52-week open-label extension). View Source

    8. DrugBank — Bremelanotide: pharmacokinetic parameters, protein binding, and route of elimination. View Source

    9. Palatin Technologies — Publication of the Vyleesi® functional MRI study in women with hypoactive sexual desire disorder. View Source

    10. BenchChem — Bremelanotide peptide stability and storage conditions: lyophilized storage at −20 °C for optimal long-term stability. View Source

    11. PMC (2017) — Usefulness of ambulatory blood pressure monitoring to assess the cardiovascular effects of bremelanotide. Randomized, double-blind, placebo-controlled study. View Source

    12. J Clin Pharmacol (2022) — Safety profile of bremelanotide across the clinical development program. Nausea most common reason for discontinuation; focal hyperpigmentation reported. View Source

    13. Proc Natl Acad Sci USA (2004) — Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. View Source

    14. Clin Ther (2017) — Phase I randomized placebo-controlled, double-blind study of the safety, tolerability, and hemodynamic effects of bremelanotide coadministered with ethanol. View Source


    ⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. PT-141 (Bremelanotide) is sold exclusively as a research compound. While bremelanotide has been FDA-approved as Vyleesi® for a specific indication, the research peptide sold here is supplied exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

    Purchase PT-141 (Bremelanotide) for Research →